Home » Topics » Regulatory » EMA

EMA
RSS

Adaptimmune Therapeutics gains access to EMA's PRIME initiative for T-cell therapy

July 29, 2016

Omeros receives scientific advice from EMA on phase III program for OMS-721

July 29, 2016

EMA grants PRIME designation to DNX-2401 for recurrent glioblastoma

July 28, 2016

Ebola Zaire vaccine wins FDA breakthrough therapy designation and PRIME status

July 26, 2016

EMA's CHMP adopts positive opinion on type II variation application for Gilead's Truvada

July 25, 2016

EMA committee supports approval of Eisai's Kisplyx

July 25, 2016

EMA's CHMP grants positive opinion to Cabometyx in RCC

July 25, 2016

EMA committee recommends approval of Onivyde in E.U.

July 25, 2016

EMA proposes changes to guidance on first-in-human trials

July 22, 2016

EMA grants orphan drug designation to XOMA-358

July 21, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...